Obesity Clinical Trial
Official title:
The Effect of Body Weight on Vitamin D Metabolism
There is current interest in the role of vitamin D in the prevention and treatment of many
chronic diseases, including osteoporosis, cancer and neurological disease. The majority of
vitamin D in the UK comes from the action of sunlight on skin, and very little from dietary
sources. Half of the adult United Kingdom (UK) population have vitamin D insufficiency
(according to the Institute of Medicine definition). There are still several important
unknowns, including what the optimum levels of vitamin D are, and whether the same intake of
vitamin D is appropriate for all sections of the population.
Low 25(OH)D and high parathyroid hormone (PTH) have been observed in people with high
adiposity (obesity), and the summer rise in vitamin D is blunted in obesity. The potential
causes of low 25(OH)D levels include an inadequate supply of vitamin D (by reduced sunlight
exposure or poor nutrition), the large pool size of adipose tissue or increased metabolic
clearance rate.
The investigators will measure metabolites of vitamin D and the kinetics of 25(OH)D using
stable isotope techniques in lean, overweight and obese men, women and children to establish
whether age, gender and obesity affect vitamin D metabolism and clearance rate.
If low 25(OH)D in obesity is related to poorer skeletal health and is due to increased
clearance of 25(OH)D or large pool size, then total requirements, and hence supplementation
requirements, would be larger for obese people than for lean people.
Part 1: Measurement of vitamin D and metabolites (adults and children) Circulating levels of
vitamin D metabolites are influenced by calcium intake, so participants will be asked to
complete a seven day diet diary before the first vitamin D measurement. Measured vitamin D
is influenced by vitamin D binding protein, lipids and inflammatory cytokines, so the
investigators will include and correct for these measurements.
Visit 1 Consent Height and weight Diet diary instructions Urine collection instructions
Visit 2 Return of 24h urine collection for calcium and creatinine Return of diet diary
Fasting blood sample for vitamin D, binding protein and metabolites C reactive protein
(CRP), lipids and creatine kinase (CK), PTH, insulin-like growth factor -1 (IGF-1),
creatinine, calcium, albumin, phosphate
Part 2: Measurement of vitamin D clearance rate (adults only) Kinetic studies will be
perturbed by acute changes in vitamin D (most likely to be caused by sunlight exposure on a
sunny day), and so the studies will all be conducted in the autumn, winter, and early spring
when sunlight in Sheffield will not be strong enough to deliver large doses of vitamin D.
The administration and sampling protocol for the kinetics study has been developed by
statisticians at the Sheffield School of Health and Related Research (ScHaRR) in
collaboration with the Medical Research Council Human Nutrition Unit, based on modelling
from their previous use of the stable isotope tracer method.
Visit 2 Oral administration of stable vitamin D isotope
Visit 3 (5-7 days after visit 2) Blood sample for tracer and vitamin D metabolites
Visit 4 (9 days ± 2 after visit 2) Blood sample for tracer and vitamin D metabolites
Visit 5 (27 days ± 2 after visit 2) Blood sample for tracer and vitamin D metabolites
Visit 6 (30 days ± 2 after visit 2) Blood sample for tracer and vitamin D metabolites Height
and weight
The effect of obesity on vitamin D metabolites will be determined by regression models of
BMI and vitamin D measurements corrected for age and gender.
The effects of obesity on vitamin D kinetics will be determined by modelling metabolic
clearance rate on age, gender and BMI.
Subjects' previous data from the 'Effects of obesity on bone structure and strength'study
(STH 15688) and the 'Body weight and bone' study (STH16199) will be used to evaluate
relationships between vitamin D metabolism and body fat distribution, bone density and
structure, and bone biochemistry.
;
Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |